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https://doi.org/10.1016/j.celrep.2021.109383SUMMARYDNAdouble-strand breaks (DSBs) are repairedmainly by non-homologous end joining (NHEJ) or homologous
recombination (HR). RIF1 negatively regulates resection through the effector Shieldin, which associateswith a
short 30 single-stranded DNA (ssDNA) overhang by the MRN (MRE11-RAD50-NBS1) complex, to prevent
further resection and HR repair. In this study, we show that RIF1, but not Shieldin, inhibits the accumulation
of CtIP at DSB sites immediately after damage, suggesting that RIF1 has another effector besides Shieldin.
We find that protein phosphatase 1 (PP1), a known RIF1 effector in replication, localizes at damage sites
dependent on RIF1, where it suppresses downstream CtIP accumulation and limits the resection by the
MRN complex. PP1 therefore acts as a RIF1 effector distinct from Shieldin. Furthermore, PP1 deficiency in
the context of Shieldin depletion elevates HR immediately after irradiation. We conclude that PP1 inhibits
resection before the action of Shieldin to prevent precocious HR in the early phase of the damage response.INTRODUCTION
Double-strand breaks (DSBs) are known to be repairedmainly by
non-homologous end joining (NHEJ) or homologous recombina-
tion (HR), and failure of these repair mechanisms causes cell
death, chromosome rearrangement, and carcinogenesis (Sy-
mington and Gautier, 2011). NHEJ is active throughout the cell
cycle (Shibata and Jeggo, 2020; Symington and Gautier, 2011)
and is used for programmed DSB repairs, such as V(D)J recom-
bination and immunoglobulin class switching (Di Virgilio et al.,
2013; Difilippantonio et al., 2008; Zimmermann and de Lange,
2014). Alternatively, HR is activated during S and G2 phases
and is initiated by a nucleolytic process called DNA end resec-
tion, which removes nucleotides from 50 DSB ends. This forma-
tion of single-stranded DNA (ssDNA) by resection of DSB ends is
essential for the process of Rad51-mediated strand invasion
(Shibata and Jeggo, 2020; Symington and Gautier, 2011). The
onset of resection blocks restorative repair by NHEJ and instead
favors DSB repair by HR (Densham and Morris, 2019; Shibata
and Jeggo, 2020; Symington and Gautier, 2011). Therefore, the
DSB resection process is a critical step for the choice of repair
pathways.
The DSB resection process is initially activated by BRCA1
(Cruz-Garcı́a et al., 2014; Densham and Morris, 2019), which
was originally identified based on the causative role of brca1mu-
tations in familial breast cancer (Miki et al., 1994). BRCA1 binds
to CtIP phosphorylated by cyclin-dependent kinase (Cruz-Gar-
cı́a et al., 2014; Densham and Morris, 2019). PhosphorylatedThis is an open access article under the CC BY-NCtIP also associates with NBS1, a component of the MRN
(MRE11-RAD50-NBS1) complex, to activate MRE11 nuclease
activity for the initiation of resection (Cruz-Garcı́a et al., 2014;
Densham and Morris, 2019; Hoa et al., 2015; Reginato and
Cejka, 2020; Takeda et al., 2016). The combined action of
BRCA1-CtIP and MRN-CtIP is suggested to generate a short
30 ssDNA tail, which undergoes further DNA end resection by
exonucleases such as EXO1 to create a longer stretch of ssDNA
(Roy et al., 2011). Loss of either BRCA1 or CtIP results in a severe
defect in HR repair, implying that the phosphorylation-depen-
dent BRCA1-CtIP and MRN-CtIP interactions play a critical
role in HR by promoting DSB resection (Cruz-Garcı́a et al.,
2014; Densham and Morris, 2019; Hoa et al., 2015; Huertas
and Jackson, 2009).
In contrast to the HR-promoting role of the BRCA1-CtIP and
MRN-CtIP interactions, the 53BP1-RIF1 complex is known to
inhibit the DSB resection process to suppress HR (Bunting
et al., 2010; Zimmermann and de Lange, 2014). Following DNA
damage, 53BP1 accumulates on DSB sites and is phosphory-
lated on S/T-Q sites by ATM kinase. Phosphorylation of 53BP1
causes recruitment of RIF1, and the resulting 53BP1-RIF1 com-
plex inhibits the accumulation of BRCA1 on DSBs and conse-
quent resection, thereby opposing HR. RIF1 is antagonized by
SCAI, a recently revealed novel 53BP1 interactor, which is re-
cruited through phosphorylated S/T-P sites on 53BP1 (Isobe
et al., 2017). SCAI binding to 53BP1 promotes the association
with DSB sites of HR factors, such as BRCA1, by inhibiting




OPEN ACCESS53BP1 is therefore subject to multiple layers of regulation
involving RIF1 and SCAI to ensure an appropriate choice be-
tween NHEJ and HR repair.
Recent studies have described the Shieldin complex as
an effector of 53BP1-RIF1. Shieldin consists of the SHLD1
(C20orf96), SHLD2 (FAM35A), SHLD3 (CTC-534A2.2), and RE
V7 proteins, which were identified as causing resistance of
BRCA1-deficient cells to PARP inhibitors when mutated (Dev
et al., 2018; Gupta et al., 2018; Noordermeer et al., 2018; Xu
et al., 2015). Shieldin accumulates at DSBs in a 53BP1-RIF1-
dependent manner (Dev et al., 2018; Findlay et al., 2018; Ghez-
raoui et al., 2018; Gupta et al., 2018; Mirman et al., 2018; Noor-
dermeer et al., 2018; Setiaputra and Durocher, 2019; Tomida
et al., 2018). Dysfunction of the Shieldin complex impairs repair
through the NHEJ pathway (including class-switch recombina-
tion) and leads to excessive DNA end resection (Dev et al.,
2018; Findlay et al., 2018; Ghezraoui et al., 2018; Gupta et al.,
2018; Mirman et al., 2018; Noordermeer et al., 2018; Setiaputra
and Durocher, 2019). Shieldin was shown to bind to the short
stretch of ssDNA produced by CtIP and MRN, where it inhibits
further resection, opposing the formation of extended ssDNA
that would direct HR (Dev et al., 2018; Findlay et al., 2018; Ghez-
raoui et al., 2018; Noordermeer et al., 2018). Shieldin also re-
cruits DNA polymerase a/primase (Pola) to fill in the resected
ends, enabling their ligation through the NHEJ pathway (Mirman
et al., 2018). The discovery of the Shieldin complex uncovered
the molecular mechanism through which 53BP1-RIF1 represses
extended resection and HR, which requires a relatively long
stretch of ssDNA. However, the extent to which 53BP1-RIF1
steers repair pathway choice at unresected DSB ends has re-
mained unclear.
In this study, we identify PP1 as an effector of RIF1 acting
distinctly from Shieldin in the damage response. We find that
PP1 suppresses the initiation of resection, apparently by inhibit-
ing CtIP-MRN activity in the early phase of the damage
response. In this role PP1 precedes the effect of Shieldin, which
suppresses the extension of resection after its initiation. Our
study reveals that PP1 and Shieldin work together to suppress
precocious HR, supporting the retention of DNA ends in a form
suitable for repair through NHEJ.
RESULTS
RIF1 suppresses CtIP IRIF independent of Shieldin
function
To investigate the role of RIF1 in the damage response for DSB
repair, we created RIF1 knockout (KO) HeLa cells by genome ed-
iting using a guide RNA designed 33 bp downstream of the start
codon (Figure 1A). We confirmed RIF1 gene disruption by west-
ern blotting, probingwith antibodies against both N andC termini
of RIF1 to ensure that no truncated RIF1 is present (Figure 1B).
Next, we examined how RIF1 affects DSB resection by the
CtIP-MRN complex after DNA damage (Figures 1C, S1A, and
S1B). In wild-type (WT) G2 cells, irradiation-induced foci (IRIF)
of CtIP were detected 1 h after X-ray irradiation and then gradu-
ally increased. In contrast, in RIF1 KO, CtIP IRIF were dramati-
cally increased at 0.5 h, and the high level was maintained at
subsequent time points (Figure 1C). The stimulation of CtIP2 Cell Reports 36, 109383, July 13, 2021IRIF at 0.5 h was also observed in small interfering RNA
(siRNA)-induced RIF1-deficient cells (Figures S1A and S1B;
Isobe et al., 2017). These results suggest that RIF1 suppresses
CtIP-MRN function during the early phase of the damage
response.
The Shieldin complex is an effector for RIF1 in the damage
response, protecting short ssDNA tails resected by CtIP-MRN
from more extended resection that would direct HR (Dev et al.,
2018; Findlay et al., 2018; Ghezraoui et al., 2018; Mirman et al.,
2018; Noordermeer et al., 2018; Setiaputra and Durocher,
2019). We examined the effect of removing the Shieldin compo-
nent REV7 on CtIP IRIF. REV7-depleted cells showed CtIP IRIF
levels similar to WT cells at all time points (Figures 1C, S1A,
and S1B). Similarly, depleting another Shieldin component,
SHLD2, did not significantly increase the number of CtIP IRIF
compared to the control at 0.5 h (Figures S1A and S1B).
The different effect on CtIP IRIF in RIF1 KO cells and Shieldin-
depleted cells 0.5 h after irradiation suggests that suppression of
early-stage CtIP accumulation by RIF1 is not mediated by Shiel-
din. This finding also implies that Shieldin is not the sole effector
for RIF1 at DSBs, and other effectors may be involved in sup-
pressing resection by CtIP-MRN.
PP1 accumulates on DSB sites through RIF1
We used a proteomic mass spectrometry approach to search for
additional RIF1 effectors, and identified all three subtypes of pro-
tein phosphatase 1 (PP1a, PP1b, and PP1g) (Figure S2A).
Consistently, PP1 was already demonstrated to be a physically
associated effector of RIF1 in the regulation of DNA replication
(Garzón et al., 2019; Hiraga et al., 2014, 2017; Sukackaite
et al., 2017), raising the possibility that the PP1a/b/g proteins
act as RIF1 effectors also for damage repair. PP1 proteins
have little intrinsic substrate specificity and are directed to spe-
cific substrates by their interacting proteins (Peti et al., 2013).
Reasoning that RIF1-PP1 activity is therefore likely to be similar
regardless of PP1 subtype, we analyzed PP1a as a representa-
tive of RIF1-PP1 function. To investigate whether PP1 is involved
in DSB repair control by RIF1, we analyzed whether PP1a un-
dergoes foci formation in response to irradiation. We observed
that both endogenous and ectopically expressed PP1a forms
IRIF that overlap with 53BP1 and gH2AX foci (Figure 2A), indi-
cating that PP1 is recruited to DSB sites. Quantifying foci in S/
G2 phase cells revealed that PP1a accumulated on damage sites
immediately after irradiation, with the number of PP1a IRIF hav-
ing reached a maximum at 0.5 h. Afterward, PP1a IRIF numbers
gradually reduced during the subsequent 6 h (Figure 2B). Inter-
estingly, the dynamics of PP1a after irradiation resemble
53BP1 and RIF1 but differ fromBRCA1 and CtIP, which accumu-
late later (Figures 1C and 2B). Given that RIF1 IRIF depend on
53BP1, we tested whether PP1a foci also depend on 53BP1,
consistent with PP1 tethering through RIF1 recruited to damage
sites by 53BP1 (Chapman et al., 2013; Di Virgilio et al., 2013; Es-
cribano-Dı́az et al., 2013; Isobe et al., 2017; Zimmermann et al.,
2013). Indeed, depletion of either RIF1 or 53BP1 abolished PP1
IRIF formation, causing instead PP1 localization scattered over
the nucleoplasm (Figures 2C and S2B). These results indicate
that the recruitment of PP1 to DSB sites requires 53BP1 and
RIF1. In contrast, SHLD2 or REV7 depletion did not affect the
A
C
B Figure 1. RIF1, but not Shieldin, suppresses
CtIP IRIF
(A) Schematic diagram of RIF1 gene construct on
the genome, with guide RNA sequence for
disruption by CRISPR-Cas9.
(B) Western blot of whole-cell extracts prepared
from wild-type (WT) cells and RIF1 knockout (KO)
cells, probed with indicated antibodies. Tubulin is
a loading control.
(C) CtIP IRIF in the G2 phase. Indicated cell lines
were treated with/without indicated siRNA for 48 h
and then irradiated. After irradiation (3 Gy), cells
were fixed at the indicated time (with addition of 5-
ethynyl-20-deoxyuridine [EdU] 10 min beforehand)
and immunostained with an anti-CtIP antibody,
along with Hoechst staining and EdU Click-iT
visualization. Cells in the G2 phase were assigned
based on Hoechst intensity and lack of EdU signal.
The numbers of CtIP foci in the G2 phase are
shown as bee swarm plots (left). p values were
calculated using a Mann-Whitney U test (*p <
0.001). Representative images are shown for cells
0, 0.5, and 3 h post-irradiation (right). Scale bars,
10 mm.
See also Figure S1.
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by RIF1 in a Shieldin-independent manner.
Previous studies have demonstrated that SCAI and BRCA1
antagonize the inhibitory effect of 53BP1 and RIF1 on HR
(Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Dı́az
et al., 2013; Feng et al., 2013; Isobe et al., 2017; Isono et al.,
2017). We sought to examine whether BRCA1 and SCAI are
involved in recruitment of PP1 to DSB sites. PP1a focus forma-tion was not affected by the depletion of
either SCAI or BRCA1. Instead, we found
that PP1a IRIF signal intensity and number
were increased in both BRCA1- and SCAI-
depleted cells compared to WT cells (Fig-
ures 2C and S2B) . This suggests that
more PP1 is recruited to each damage
site, potentially reflecting that the inhibition
of RIF1 function by BRCA1 or SCAI is
attenuated (Chapman et al., 2013; Isobe
et al., 2017; Isono et al., 2017).
PP1 IRIF require direct binding of
RIF1-PP1
PP1 regulates DNA metabolism and chro-
mosome maintenance through dephos-
phorylation of various target substrates
(Cohen, 2002). To focus on the function
of PP1 in DSB repair, we analyzed cells ex-
pressing a RIF1 mutant protein that is un-
able to associate with PP1. To this end,
we generated three versions of RIF1,
mutated either at a PP1 binding motif
close to the N terminus (RIF1ppN), or at
two PP1 binding motifs close to the C ter-
minus (RIF1ppC), or else mutated at allthree motifs (RIF1pp) (Figure 3A; Hiraga et al., 2017). While
RIF1ppN was still able to interact with PP1a, the RIF1ppC and
RIF1pp mutations completely abolished PP1a interaction (Fig-
ure 3B), indicating that RIF1 associates with PP1a through its
C-terminal motifs, consistent with a previous report for the
mouse RIF1 protein (Sukackaite et al., 2017). We therefore
used the C-terminal mutant (RIF1ppC) as a version of RIF1 lack-
ing PP1-binding capability. Next, we established RIF1 KO cellCell Reports 36, 109383, July 13, 2021 3
A B
C
(legend on next page)






OPEN ACCESSlines with FLAG-sfGFP-tagged RIF1 derivative (RIF1WT or
RIF1ppC) under the control of doxycycline (Dox) promoter
(designated as WTKI or ppCKI). 24 h after Dox induction the
expression levels of RIF1WT and RIF1ppC were approximately
3-fold those of endogenous RIF1 (Figure S3). Similar to endoge-
nous RIF1 in WT cells, RIF1WT and RIF1ppC formed IRIF that
overlapped with 53BP1 (Figure 3C; Isobe et al., 2017). Further-
more, RIF1WT and RIF1ppC displayed a similar number of
RIF1 IRIF, with some RIF1ppC foci appearing slightly brighter.
We suspect this reflects the fact that cells expressing RIF1ppC
accumulate phosphorylated 53BP1, likely due to defective
DSB repair, which causes increased recruitment of RIF1 onto
DSB sites. In RIF1 KO cells expressing RIF1WT (WTKI), the num-
ber of PP1a IRIF was comparable to WT cells (Figure 3C), con-
firming that RIF1 function is properly complemented by the
ectopic RIF1WT expression. Inmarked contrast, in RIF1 KO cells
expressing RIF1ppC (ppCKI), we did not detect PP1a IRIF after
irradiation, despite efficient recruitment of the RIF1ppC onto
DSB sites (Figure 3C). PP1 levels are similar in KO+RIF1ppC
(ppCKI) toWT and KO+RIF1WT cells (WTKI) (Figure S3). These re-
sults therefore suggest that direct recruitment by RIF1 is respon-
sible for PP1 IRIF formation.
RIF1-PP1 suppresses formation of CtIP IRIF in the early
phase of damage response
Even though Shieldin is an effector of RIF1, the involvement of
RIF1 in the early stage of the damage response differs from
that of Shieldin. In particular, RIF1 suppresses CtIP IRIF for-
mation immediately after irradiation, while Shieldin does not
(Figures 1C and S1A). Considering this difference, we hypoth-
esized that, as another effector of RIF1, PP1 might be involved
in regulating CtIP IRIF formation. We therefore examined how
abolishing PP1 recruitment by RIF1 affects CtIP IRIF immedi-
ately after irradiation. In the RIF1 KO cells expressing RIF1
defective for PP1 binding (ppCKI), the number of CtIP IRIF
was increased to a level similar to RIF1 KO cells (Figure 4A).
In contrast, RIF1 KO cells expressing RIF1WT (WTKI) showed
a low CtIP IRIF number similar to WT cells (Figure 4A). These
results suggest that PP1 is another effector of RIF1, acting
separately from Shieldin, that specifically suppresses CtIP
loading at DSB sites, potentially to suppress initiation of resec-
tion in the early phase of the damage response. In contrast,
Shieldin knockdown (by either siREV7 or siSHLD2) hardly
increased CtIP IRIF numbers 0.5 h after irradiation (Figures
1C, 4A, and S1A). Moreover, the number of CtIP IRIF in KO+R-
IF1ppC cells (ppCKI) was hardly affected by the presence or
absence of SHLD2 (Figure 4A). It therefore appears that sup-
pression of CtIP foci by RIF1 is mediated principally by PP1Figure 2. PP1 IRIF depends on RIF1
(A) PP1a IRIF. HeLa cells (upper) or HeLa cells stably expressing GFP-PP1a (low
PP1a, anti-53BP1, and anti-gH2AX antibodies. GFP-PP1a was detected as GFP
(B) Time course analysis of IRIF for PP1a, 53BP1, RIF1, and BRCA1 in S/G2 cell
fixation for immunofluorescence. Cells were immunostained with antibodies again
phase were assigned based on cyclin A intensity. Numbers of foci are shown as
(C) Dependency of PP1 IRIF on RIF1 and 53BP1. WT or RIF1 KO cells were treate
immunostaining with anti-PP1a and anti-53BP1 antibodies. The numbers of PP1a
See also Figure S2.in the early phase of damage response, with the Shieldin com-
plex playing only a minor role at this stage.
RIF1-PP1 suppresses CtIP-BRCA1 and CtIP-MRN PLA
interactions
As shown above, RIF1-PP1 suppresses CtIP loading at DSB
sites. Since CtIP loading at DSBs occurs through interaction of
phosphorylated CtIP with BRCA1 and MRN, we examined
whether RIF1-PP1 suppresses CtIP phosphorylation. We first
tested the effect of RIF1-PP1 on the phosphorylation status of
CtIP by an electrophoretic mobility shift assay (Wang et al.,
2013). In RIF1 KO or KO+RIF1ppC cells with DNA damage,
phosphorylated forms of CtIP were more abundant than in WT
and KO+RIF1WT, indicating that in the absence of RIF1-PP1,
CtIP phosphorylation is intensified (Figure S4A). Therefore,
RIF1-PP1 might have a function in dephosphorylation of CtIP.
We next investigated the effect of RIF1-PP1 on the recruitment
of CtIP-BRCA1 to DSB sites. To this end, we exposed the cells to
irradiation and subsequently performed a proximity ligation
assay (PLA) to test CtIP-BRCA1 interaction. Similar to CtIP
IRIF, BRCA1 IRIF formation was stimulated in RIF1- or RIF1-
PP1-deficient cells 0.5 h after irradiation, but it exhibited only a
subtle increase in SHLD2-depleted cells (Figure 4B). Further-
more, PLA interaction between CtIP and BRCA1 was stimulated
in RIF1- or RIF1-PP1-deficient cells, but not in SHLD2-depleted
cells (Figures 4C and S4B). These observations indicate that
RIF1-PP1 suppresses recruitment of CtIP and BRCA1 at dam-
age sites by inhibiting the interaction of CtIP with BRCA1, prob-
ably by inhibiting CtIP phosphorylation.
In contrast to CtIP and BRCA1, the number of NBS1 foci
formed in immediate response to irradiation did not differ
between the cell lines examined (including RIF1- or RIF1-PP1-
deficient cells), indicating that loading of MRN at damage sites
is independent of RIF1 (Figure 4B; Falck et al., 2012). Nor were
NBS1 foci affected by siRNA against SHLD2. However, PLA
interaction between CtIP and NBS1 was increased in RIF1 KO
and in KO+RIF1ppC cells (Figures 4C and S4B). These results
suggest that phosphorylated CtIP associates with MRN through
NBS1 on damage sites, and RIF1-PP1 might suppress the CtIP-
MRN association through dephosphorylation of CtIP, in turn pre-
venting the initiation of resection.
RIF1-PP1 contributes to suppression of MRN
exonuclease-dependent resection in the early phase of
the damage response
In PLA experiments we discovered enhanced interactions of
CtIP-BRCA1 and CtIP-NBS1 in RIF1-PP1-deficient cells (Fig-
ure 4C). These findings raise the possibility of elevated initiationer) were irradiated (3 Gy) and then 1 h later fixed for immunostaining with anti-
signal. Scale bars, 10 mm.
s. Cells were irradiated (3 Gy) and incubated for the indicated periods prior to
st indicated proteins and cyclin A, alongwith Hoechst staining. Cells in the S/G2
a bee swarm plot.
d with indicated siRNA for 48 h and irradiated (3 Gy) and then 1 h later fixed for
foci are shown as bee swarm plots (p < 0.001 for WT siCont). Scale bar, 10 mm.
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Figure 3. PP1 IRIF depends on the direct binding to RIF1
(A) Schematic structure of RIF1 indicating its three PP1 binding motifs and the mutants created.
(B) Testing PP1 binding for the mutants created. T-REx 293 cells were transfected with expression plasmids for the indicated constructs. FLAG-RIF1 immu-
noprecipitates were analyzed by western blotting by the indicated antibodies.
(C) Cell lines with endogenous RIF1 replaced by the mutant deficient in PP1 binding. Cells were irradiated (3 Gy) 24 h after doxycycline (Dox) induction. Then, 1 h
later, the cellswere fixed for immunostainingwith anti-PP1a and anti-53BP1 antibodies. KO+RIF1WT (WTKI), RIF1KOcell withDox-inducible FLAG-sfGFP-tagged
WT RIF1; KO+RIF1ppC (ppCKI), RIF1 KO cell with Dox-inducible FLAG-sfGFP-tagged mutant deficient in PP1 binding. Dox-induced FLAG-sfGFP-tagged RIF1
derivatives were detected as GFP signal. The numbers of GFP-tagged RIF1 derivatives, PP1a, and 53BP1 foci are shown as bee swarm plots. Scale bar, 10 mm.
See also Figure S3.
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Figure 4. RIF1-PP1 interaction suppresses
CtIP and BRCA1 IRIF and limits CtIP-BRCA1
and CtIP-NBS interactions as assessed by
PLA
(A) RIF1 function in CtIP IRIF in G2 cells. 48 h after
transfection by siRNA and 24 h after Dox addition,
the indicated cell lines were irradiated (3 Gy) 0.5 h
before fixation (with EdU addition 10 min before
fixation). Cells were immunostained with anti-CtIP
antibody, along with Hoechst staining and EdU
Click-iT visualization. Cells in the G2 phase were
assigned as in Figure 1C. WTKI (KO+RIF1WT cell)
and ppCKI (KO+RIF1ppC cell) as in Figure 3C.
Numbers of CtIP foci in G2 phase cells are shown as
bee swarm plots. p values were calculated using a
Mann-Whitney U test (*p < 0.001).
(B) Effect of RIF1 on BRCA1 and NBS1 IRIF. 48 h
after transfection by siRNA and 24 h after Dox
addition, indicated cell lines were irradiated (3 Gy)
0.5 h before fixation. Cells were immunostained
with anti-BRCA1 or anti-NBS1 antibodies along
with cyclin A immunostaining and Hoechst stain-
ing. The G2 cells were assigned based on cyclin A
intensity. WTKI and ppCKI are as in Figure 3C.
Numbers of BRCA1 (left) or NBS1 (right) foci in the
G2 phase are shown as bee swarm plots. p values
were calculated using a Mann-Whitney U test
(*p < 0.001).
(C) Effect of RIF1 on BRCA1-CtIP and NBS1-CtIP
interaction tested by PLA. 48 h after transfection
by siRNA and 24 h after Dox addition, indicated
cell lines were irradiated (3 Gy) 0.5 h before fixa-
tion. Cells were immunostained with anti-CtIP
antibody and anti-BRCA1 or anti-NBS1 anti-
bodies, and then in situ ligation and amplification
reactions were performed. DNA was stained with
DAPI. WTKI and ppCKI are as in Figure 3C.
Numbers of PLA signal in nucleolus are shown as
bee swarm plots. p values were calculated using a
Mann-Whitney U test (*p < 0.001).
See also Figure S4.
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OPEN ACCESSof resection with an increase in short ssDNA exposure due to
CtIP-MRN activity. To examine this possibility, we visualized
ssDNA-binding protein RPA as a proxy for ssDNA caused by
end resection. In RIF1 KO cells and in cells expressing RIF1 inca-
pable of PP1 binding, the number of RPA foci was increased at
0.5 h after irradiation, compared to control cells (compare col-
umns 1, 3, and 7, Figure 5A). An increased number of RPA foci
was also observed in SHLD2-depleted cells (column 9). To inves-
tigate how an effect of RIF1-PP1 on MRE11 nuclease activity
may contribute to ssDNA and RPA foci, we treated cells with
the MRE11 exonuclease inhibitor Mirin before irradiation. The in-
crease in RPA foci in KO+RIF1ppC cells was completely abol-
ished by mirin treatment, indicating that the ssDNA caused by
loss of RIF1-PP1 is generated by MRE11 exonuclease activity
(column 8, Figure 5A). In contrast, RPA foci in SHLD2-depleted
cells were hardly affected by mirin (column 10), suggesting that
the elevated RPA foci in Shieldin-depleted cells reflect ssDNA
resection by an exonuclease other than MRN, possibly Exo1.We conclude that PP1 is an effector of RIF1 acting quite distinct
from Shieldin, and it is particularly involved in suppressing
ssDNA exposure by inhibiting the initiation of resection by
CtIP-MRN in the early phase of the damage response. In the
case of RIF1 KO cells, the increase in RPA foci 0.5 h after irradi-
ation was noticeably but not completely prevented bymirin treat-
ment (column 4, Figure 5A). We interpret the mirin-resistant in-
crease in RPA in RIF1 KO cells as indicative of ssDNA
occurring due to failed Shieldin recruitment. The substantial ef-
fect of mirin 0.5 h after irradiation indicates the important contri-
bution of PP1 for RIF1 function immediately after irradiation,
when its effect dominates over that of Shieldin.
PP1 cooperates with Shieldin to suppress HR repair in
the early phase of the damage response
To further investigate the functional relationship between PP1
and Shieldin as effectors of RIF1, we analyzed IRIF of RAD51,





Figure 5. Suppression of precocious HR by
PP1 in cooperation with Shieldin
(A) RIF1 effect on RPA IRIF in G2 cells. 48 h after
transfection by siRNA and 24 h after Dox addition,
indicated cell lines were irradiated (3 Gy) 0.5 h
before fixation (with addition of EdU 10 min be-
forehand) in the absence or the presence of the
MRE11 exonuclease inhibitor mirin. Cells were
immunostained with anti-RPA2, along with
Hoechst staining and EdU Click-iT visualization.
Cells in the G2 phase were assigned as in Fig-
ure 1C. WTKI and ppCKI are as in Figure 3C. The
numbers of RPA2 IRIF in the G2 phase cells are
shown as bee swarm plots. p values were calcu-
lated using a Mann-Whitney U test (*p < 0.001 for
WT + siCont; **,***p < 0.001 for the respective no-
mirin conditions).
(B) RIF1 function in RAD51 IRIF in S/G2 cells. 48 h
after transfection by siRNA and 24 h after Dox
addition, the indicated cell lines were irradiated (3
Gy) 0.5 or 3 h before fixation. Cells were immu-
nostained with anti-RAD51 and anti-cyclin A anti-
bodies with Hoechst staining. Cells in the S/G2
phase were assigned based on cyclin A intensity.
WTKI and ppCKI are as in Figure 3C. The numbers
of RAD51 IRIF in the S/G2 phase cells are shown
as bee swarm plots. p values were calculated
using a Mann-Whitney U test (*p < 0.001).
(C) Olaparib sensitivity in BRCA1-deficient cells.
The cells were treated with olaparib for 72 h after
transfection with siRNA against control (left) or
BRCA1 (right), plating a fixed number of cells, and
Dox addition. During the period for olaparib
treatment, RIF1WT and RIF1ppC were constantly
supplied by Dox induction even in the presence or
absence of BRCA1 or olaparib (Figure S5A). Indi-
cated cell lines treated with either control or
BRCA1 siRNA was examined using a colony for-
mation assay (Figure S5B). WTKI and ppCKI are as
in Figure 3C. Numbers of colonies were stan-
dardized relative to those not treated with PARP
inhibitor (mean ± SD; n = 2 experiments).
(D) Model for function of RIF1 in the damage
response with two effectors, PP1 and Shieldin.
RIF1 negatively regulates HR and directs NHEJ
through two distinct pathways: through PP1
recruitment inhibiting initiation of resection, and
through Shieldin recruitment inhibiting further,
extended resection. See Discussion for details.
See also Figure S5.
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OPEN ACCESSa significant increase in RAD51 IRIF in RIF1 KO cells when
compared with WT (Figure 5B, left), indicating that RIF1 is
required to suppress HR in the early stage of the damage
response. A significant increase in RAD51 IRIF was also
observed in cells expressing RIF1 incapable of PP1 binding
(KO+RIF1ppC) when compared to KO+RIF1WT cells, but the
extent was less than in RIF1-deficient cells. No increase in
RAD51 IRIF was, however, observed in Shieldin-depleted cells,
compared with WT (Figure 5B, left). These data suggest that
the RIF1-PP1 pathway is dominant in suppressing HR in the early
stage of the damage response, with the effect of the RIF1-Shiel-8 Cell Reports 36, 109383, July 13, 2021din pathway beingminimal when RIF1-PP1 is functional. Howev-
er, combined loss of RIF1-PP1 interaction and Shieldin depletion
caused a further increase in RAD51 IRIF number, with an effect
similar to RIF1 KO (Figure 5B, left). This result suggests that
PP1 and Shieldin function independently, and Shieldin has little
function in suppressing HR at the early stage. However, when
resection is initiated by CtIP-MRN in the absence of RIF1-PP1
activity, Shieldin is required to suppress further extension of
ssDNA for HR (Dev et al., 2018; Findlay et al., 2018; Ghezraoui
et al., 2018; Gupta et al., 2018; Mirman et al., 2018; Noordermeer
et al., 2018; Tomida et al., 2018). RIF1 deletion also increased the
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OPEN ACCESSnumber of RAD51 IRIF even at 3 h post-irradiation (Figure 5B,
right). At this later stage, we found that SHLD2 depletion
increased the number of RAD51 IRIF independent of PP1 func-
tion, indicating that the relative contribution of Shieldin to HR in-
hibition increases at later phase of damage response. This
finding is consistent with reports that a functional deficiency in
Shieldin alone promotes HR (Findlay et al., 2018; Tomida et al.,
2018). In summary, we find that PP1 delays the onset of HR prin-
cipally in the early response phase, whereas the contribution
made by Shieldin to HR suppression increases as the response
develops.
PP1 did not show suppression of PARP inhibitor
sensitivity in the BRCA1-depleted background
We showed that RIF1-PP1 function in suppression of HR is
limited to the early response phase, followed by a larger contri-
bution of RIF1-Shieldin at a later stage. Therefore, we hypothe-
sized that even if PP1 recruitment by RIF1 fails, RIF1-Shieldin
function is nonetheless ultimately sufficient to protect DNA
ends and direct cells to use NHEJ. To test this possibility, we
examined the sensitivity of BRCA1-depleted RIF1 KO cells to
the PARP inhibitor olaparib by clonogenic cell survival assay.
This test is based on the supposition that olaparib generates
one-ended DSBs in S phase cells, which must be repaired pre-
dominantly by HR for survival (Lord and Ashworth, 2013). It was
previously shown that either RIF1 or Shieldin depletion sup-
presses the sensitivity of BRCA1-deficient cells to olaparib, pre-
sumably because enhanced resection in the absence of Shiel-
din can promote HR even when BRCA1 is lacking (Escribano-
Dı́az et al., 2013; Findlay et al., 2018; Ghezraoui et al., 2018;
Gupta et al., 2018; Mirman et al., 2018; Noordermeer et al.,
2018; Xu et al., 2015). If deficiency of RIF1-PP1 function can
be compensated by RIF1-Shieldin, then failure of RIF1 to recruit
PP1 will not suppress sensitivity to olaparib in the BRCA1-
depleted context.
For the clonogenic cell survival assay, a fixed number of cells
was plated with Dox induction, then 24 h later the cells were
treated with olaparib for 72 h (Figures 5C, S5A, and S5B). In
the presence of BRCA1, RIF1 KO cells, RIF1 KO cells expressing
RIF1WT, and RIF1 KO cells expressing RIF1 lacking PP1 binding
did not show olaparib sensitivity, compared with WT cells. As
previously demonstrated, in the BRCA1-depleted background,
RIF1 KO partially suppressed the sensitivity to PARP inhibitor
(Figure 5C; Dev et al., 2018; Escribano-Dı́az et al., 2013; Noor-
dermeer et al., 2018; Xu et al., 2015). Notably, however, the
BRCA1-depleted RIF1 KO cells expressing RIF1 deficient for
PP1 binding showed no suppression of PARP inhibitor sensi-
tivity, but rather they showed sensitivity similar to BRCA1-
depleted WT cells (Figure 5C). These results indicate that the
RIF1-Shieldin pathway can compensate for defects in the
RIF1-PP1 pathway to maintain sensitivity to olaparib-induced
DNA damage. To confirm this idea, we performed reporter
assays directly monitoring repair through NHEJ or HR at a site-
specific DSB (Figure S5C). Consistent with the results from a clo-
nogenic cell survival assay, RIF1-depleted cells expressing
mCherry-tagged RIF1ppC showed similar HR and NHEJ fre-
quencies to control cells (compare columns 1, 5, and 6 in
graphs). In marked contrast, Shieldin depletion (column 7) signif-icantly enhanced HR and suppressed NHEJ frequencies as
observed in RIF1 depletion (column 4). Furthermore, gH2AX ki-
netics showed damage persistence, with an increased number
of gH2AX IRIF observed at 8 h in RIF1- or SHLD2-deficient situ-
ations (Shibata et al., 2011). RIF1-PP1 deficiency alone, howev-
er, did not result in damage persistence (Figure S5D). These
observations support our model where RIF1-PP1 acts to regu-
late resection primarily early in the damage response, acting in
a different stage of the pathway from the RIF1-Shieldin axis (Fig-
ure 5D). Moreover, these results support the idea that despite
early over-recruitment of CtIP that induces precocious initiation
of resection when RIF1-PP1 is absent, Shieldin can nonetheless
compensate at a later stage for PP1 deficiency to ultimately sup-
port the use of NHEJ.
DISCUSSION
53BP1-RIF1 is a critical interaction for the correct choice of
NHEJ-mediated repair in the damage response (Zimmermann
and de Lange, 2014). In this study, we have shown that PP1
acts alongside Shieldin as an effector of RIF1 in directing DSB
repair (Figure 5D).
Previous studies have shown that Ku70/80 binds rapidly to
DSBs, allowing NHEJ to make the first repair attempt in the
absence of resection (Britton et al., 2013; Frank-Vaillant and
Marcand, 2002; Kim et al., 2005; Shibata et al., 2011; Shibata
and Jeggo, 2020). Our results suggest that RIF1-PP1 plays a
role in this situation. This study shows that PP1 binds to RIF1
at damage sites and inhibits CtIP IRIF. Consistently, RIF1-PP1
suppressed early RPA focus formation. RPA focus formation in
the absence of RIF1-PP1 was mirin-sensitive; thus, RIF1-PP1 in-
hibits initiation of CtIP-MRN-mediated resection that provides
ssDNA for Shieldin engagement. This effect of RIF1-PP1 poten-
tially promotes NHEJ for immediate damage repair (Figure 5D). If
NHEJ does not ensue (Reginato and Cejka, 2020; Shibata et al.,
2011; Shibata and Jeggo, 2020), phosphorylated CtIP stimulates
MRN nuclease to produce short resected ssDNA ends (Hoa
et al., 2015; Huertas and Jackson, 2009; Reginato and Cejka,
2020; Sartori et al., 2007; Symington and Gautier, 2011; Takeda
et al., 2016). Shieldin binds to the ssDNA at this stage to prevent
extended resection that would direct repair toward HR (Dev
et al., 2018; Findlay et al., 2018; Ghezraoui et al., 2018; Mirman
et al., 2018; Noordermeer et al., 2018; Setiaputra and Durocher,
2019; Tomida et al., 2018): after the refilling of ssDNA by Pola,
the Shieldin-bound ssDNA ends can be repaired by NHEJ (Mir-
man et al., 2018; Setiaputra and Durocher, 2019). RIF1-PP1
might also protect such re-filled ends from renewed resection
to keep them in a state suitable for joining. If NHEJ does not
ensue, Shieldin protection would be lifted, clearing the way for
further end resection by exonuclease activities such as MRE11
and EXO1 to produce a length of ssDNA sufficient for HR (Dev
et al., 2018; Findlay et al., 2018; Ghezraoui et al., 2018; Mirman
et al., 2018; Noordermeer et al., 2018; Setiaputra and Durocher,
2019; Tomida et al., 2018). Therefore, we propose that RIF1
negatively regulates HR and directs NHEJ by distinct two path-
ways: through PP1 to inhibit short-range resection by CtIP-
MRN, and then by Shieldin recruitment to inhibit further extended
resection (Figure 5D).Cell Reports 36, 109383, July 13, 2021 9
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OPEN ACCESSRIF1-PP1 functions with Shieldin to prevent HR as monitored
by visualizing RAD51 IRIF, with this role significant mainly in the
early phase of damage response. We assume that, during this
period, DSBs with appropriate clean ends will be repaired by
NHEJ without initiation of resection (Figure 5D). The fact that
the function of PP1 acts primarily early in the response and
can be superseded by the alternative effector Shieldin may
explain why in several reports the deficiency of RIF1 and Shieldin
appears to be equivalent in terms of downstream phenotypes,
such as the suppression of PARP inhibitor sensitivity in
BRCA1-deficient cells, and the loss of immunoglobulin class-
switch recombination (Chapman et al., 2013; Dev et al., 2018;
Di Virgilio et al., 2013; Escribano-Dı́az et al., 2013; Feng et al.,
2013; Findlay et al., 2018; Ghezraoui et al., 2018; Mirman et al.,
2018; Noordermeer et al., 2018; Setiaputra and Durocher,
2019; Tomida et al., 2018; Zimmermann et al., 2013). Further-
more, NHEJ is defective to a similar extent in RIF1- and Shiel-
din-deficient cells, implying that Shieldin is indeed the major
effector of RIF1 for directing NHEJ (Dev et al., 2018; Ghezraoui
et al., 2018; Mirman et al., 2018; Noordermeer et al., 2018; Setia-
putra and Durocher, 2019). Most likely, if RIF1-PP1 deficiency
causes inappropriate short-range resection at damage that
should have been repaired by NHEJ prior to any resection,
then the situation can still subsequently be rescued by Shiel-
din-regulated NHEJ, thus obscuring the effect of RIF1-PP1 defi-
ciency on NHEJ repair rates. Indeed, unlike RIF1-Shieldin
deficiency, RIF1-PP1 deficiency did not show any suppression
of PARP inhibitor sensitivity in BRCA1-deficient cells, consistent
with no consequences for NHEJ or HR efficiency, or for gH2AX
kinetics. Through the RIF1-Shieldin pathway it is proposed that
DSB ends resected by CtIP-MRN are re-filled by Pola, and
then repaired by NHEJ. Shieldin has been described as promot-
ing this pathway of NHEJ. In these considerations, RIF1 has two
different functions, suppression of short-range resection (medi-
ated by PP1) and suppression of longer-range resection (medi-
ated by Shieldin), but with both pathways operating to protect
against HR and stimulate NHEJ (Figure 5D). Intriguingly, it has
been proposed that Shieldin is not always required tomediate ef-
fects 53BP1-RIF1 in repair control. During the development of
immune cells distinct NHEJ pathways operate, one Shieldin-
dependent and the other Shieldin-independent (Ghezraoui
et al., 2018), raising the possibility that RIF1-PP1 may be
required for correct pathway choice under some circumstances.
An important question is howPP1 regulates DSB repair. PP1 is
a conserved Ser/Thr protein phosphatase with indiscriminate
specificity in vitro (Cohen, 2002). RIF1 is a one of many PP1
adaptor proteins that target PP1 to physiologically relevant sub-
strates or cellular locations (Trinkle-Mulcahy et al., 2006). In DNA
replication, it has been reported that RIF1-PP1 is involved inmul-
tiple steps, including suppression of replication initiation at ori-
gins and preventing the degradation of nascent DNA at stalled
forks (Garzón et al., 2019; Hiraga et al., 2017). In replication,
RIF1-PP1 therefore appears to have several direct or indirect
target substrates (Garzón et al., 2019; Hiraga et al., 2017). Our
study indicates that RIF1-PP1 inhibits resection by MRN.
MRN-mediated resection is stimulated by phosphorylated
CtIP, suggesting that the relevant substrate of RIF1-PP1 might
be one or more of these proteins. It has been reported that the10 Cell Reports 36, 109383, July 13, 2021phosphorylation of CtIP is required for a complex formation
with BRCA1 and stimulation of MRN endonuclease activity to
facilitate the initiation of resection (Anand et al., 2019; Cruz-Gar-
cı́a et al., 2014; Reginato and Cejka, 2020). One possible mech-
anism is that PP1 may dephosphorylate CtIP to prevent it from
binding to BRCA1 and MRN, thereby inhibiting resection.
Consistently, this study showed possible involvement of RIF1-
PP1 in dephosphorylation of CtIP and suppression of CtIP-
BRCA1 and CtIP-NBS interactions as assessed by PLA. Addi-
tional mechanisms may also operate, and another candidate
substrate of RIF1-PP1 is 53BP1 itself. Several S/T-Q phosphor-
ylation sites for ATM kinase close to the N terminus of 53BP1 are
required for RIF1 binding (Zimmermann and de Lange, 2014).
These were suggested to be dephosphorylated by PP4 to lift
the block to resection by releasing RIF1 from 53BP1 (Isono
et al., 2017). In contrast, several S/T-P phosphorylation sites
close to the N terminus of 53BP1 are potentially phosphorylated
by cyclin-dependent kinase or mitogen-activated protein kinase
(MAPK) and are responsible for SCAI binding (Isobe et al., 2017).
Once SCAI binds, it inhibits RIF1 and stimulates BRCA1 IRIF
(Isobe et al., 2017), so RIF1-PP1 could potentially inhibit
BRCA1-CtIP by preventing SCAI binding to 53BP1, possibly
through dephosphorylating the S/T-P phosphorylation sites on
the 53BP1. Furthermore, DNA-PKcs (DNA-dependent protein ki-
nase, catalytic subunit), which is directly involved in NHEJ, might
be a candidate substrate of RIF1-PP1. It has been shown that
PP1 dephosphorylates autophosphorylated residues at the N
and C termini of DNA-PKcs to cause activation (Zhu et al.,
2017). Considering the RIF1 contribution to NHEJ, one possibil-
ity is that RIF1 directs the PP1, which dephosphorylates DNA-
PKcs to predominantly induce NHEJ (Zhu et al., 2017). Of
course, multiple layers of dephosphorylation-mediated control
could affect DNA-PKcs, BRCA1, CtIP, the MRN complex,
53BP1, RIF1, PP1, and SCAI to ensure that NHEJ and HR are
accurately conducted.
In summary, our results demonstrate that PP1 functions as a
RIF1 effector that counteracts initiation of resection at an early
stage of repair, promoting NHEJ-mediated repair prior to Shiel-
din function. Having established this role for RIF1-PP1, further
elucidation of PP1 and Shieldin functions as effectors for RIF1
in the damage response will substantially enhance our under-
standing of robust and flexible repair pathway choice.STAR+METHODS
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OPEN ACCESSEXPERIMENTAL MODEL AND SUBJECT DETAILS
Flp-In-T-REx 293 (Life Technologies), HeLa, and their derivatives were grown in D-MEM (nacalai tesque) supplementedwith 5%Fetal
Bovine Serum (FBS, Life Technologies) and 100 mg/ml of penicillin and 100 unit/ml of streptomycin (Life Technologies) in 5% CO2 at
37C. For U2OS EJ5-GFP and U2OS DR-GFP, the same medium supplemented with 10% FBS was used.
METHOD DETAILS
Drug treatment
Doxycycline (Dox, Sigma-Aldrich) was added to cell culture at 1 mg/ml 24h before irradiation. Mirin (MRE11 exonuclease inhibitor,
Abcam) was added to cell culture at 100 mM 10 min before irradiation. KU55933 (ATM inhibitor, Abcam) was added to cell culture
at 10 mM 10 min before the addition of Neocarzinostatin. Neocarzinostatin (Sigma-Aldrich) was added to cell culture at 150 ng/ml.
RNA interference
RNA interference (RNAi) was performed as described (Nozawa et al., 2010). Briefly, cells were transfected with 20 nM siRNAs using
Lipofectamine RNAiMAX (Thermo Fisher). Oligonucleotides (Supplier, identification numbers) used for RNAi in this study are as fol-
lows: RIF1 (Dharmacon, #D-027983-02), RIF1-2 (Thermo Fisher, # HSS124071), REV7 (Thermo Fisher, #s20466), SHLD2 (Thermo
Fisher, #HSS147691), 53BP1 (Thermo Fisher, # HSS110909), SCAI (Thermo Fisher, # HSS138873), BRCA1 (Thermo Fisher, #
HSS186097). Oligonucleotides used for control siRNA: (sense); 5ʹ-GUACCGCACGUCAUUCGUAUC-3ʹ and (anti-sense); 5ʹ-UAC
GAAUGACGUGCGGUACGU-3ʹ (Nozawa et al., 2010).
Antibodies
For primary antibody (host animal, supplier, identification clone name and dilution with applications) used in this study are as follows:
anti-RIF1 (goat; sc-55979; Santa Cruz; 1:300 for western blotting (WB) and 1:500 for immunofluorescence (IF)), anti-RIF1 (rabbit;
A300-569A; Bethyl; 1:500 for WB), PP1 (mouse; sc-7482; Santa Cruz; 1:500 for WB), anti-PP1a (goat; sc-6104; Santa Cruz; 1:500
for IF), CtIP (mouse; 14-1; Active Motif, 1:500 for WB, 1:300 for IF), anti-gH2AX (mouse; JBW301, Millipore, 1:5000 for IF), anti-
gH2AX (rabbit; 20E3, CST, 1:500 for IF), anti-REV7 (rabbit; EPR13657; abcam; 1:500 forWB), anti-RAD51 (rabbit polyclonal antibody;
a gift from Hitoshi Kurumizaka; 1:3000 for IF) (Tachiwana et al., 2006), anti-53BP1 (rabbit; NB 100-304; Novus Biologicals; 1:1000 for
WB and 1:5000 for IF), anti-SCAI (mouse; 17C3; described previously; hybridoma culture supernatants were used at 1:100 for WB)
(Isobe et al., 2017), anti-BRCA1 (rabbit; 07-434; Millipore; 1:500 for WB), anti-NBS1 (rabbit; NB 100-143; Novus Biologicals; 1:500 for
IF), anti-RPA2 (mouse; 9H8; abcam; 1:300 for IF), anti-cyclin A (mouse; CY-A1; Sigma; 1:1000 for IF), anti-Tubulin (mouse; DM1A;
Sigma; 1:10000 for WB), anti-FLAG (mouse; M2; Sigma; 1:1000 for WB). Secondary antibodies (KEY RESOURCES TABLE) were
used at 1:10000 dilution for western blot, and at 1:500 dilution for immunofluorescence.
Plasmid construction
siRNA-resistant RIF1 silent mutation was generated as that the siRNA target: 5ʹ-AGACGGTGCTCTATTGTTA-3ʹ was replaced with
5ʹ-cGtaGaTGtTCaATaGTac-3ʹ. cDNA encoding PP1a was cloned from HeLa mRNA by RT-PCR. RIF1 derivatives were generated
from plasmids described in Hiraga et al. (2017). All sequences obtained by PCR were verified by nucleotide sequencing. Detailed
information about plasmid constructions described in this paper is available on request.
Plasmid transfection and establishment of cell lines
Plasmid transfections were performed by the manufacturer’s procedures. Lipofectamine 2000 (Thermo Fisher) was used for immu-
noprecipitation experiments and Gene Juice (Millipore) for the establishment of the cell lines.
For establishment of RIF1 knock out HeLa cell (RIF1 K/O), pX330 harboring a guide RNA for RIF1 (See Key resource table) and
pPyCAG-monomeric Kusabira Orange-IRES-Pac (for puromycin selection) were co-transfected into HeLa cells. Puromycin resistant
cells were re-plated and isolated as single clones. RIF1 gene disruption was confirmed by direct-sequencing and western blotting
analysis.
For establishment of RIF1 K/O cell lines with Dox-inducible RIF1 derivatives (WTKI and ppCKI), RIF1 K/O cells were transfected with
pPBhCMV1 harboring FLAG-sfGFP-tagged RIF1WT or RIF1ppC under the control of doxycycline promoter, pPBCAG-rtTA-IRES-
Neor (for expression of reverse tetR with the C-terminal domain of VP16), and pmPB (for expression of PiggyBac transposase).
G418 resistant clones were isolated. For establishment of HeLa cell line expressing GFP-PP1a, cells were transfected with
pcDNA3.1-based GFP-PP1a expression vector and G418 resistant clones were isolated.
Immunofluorescence and microscopy
Immunofluorescence microscopy was performed essentially as described (Nozawa et al., 2013). Cells were grown on glass cover-
slips for X-ray irradiation (MX-80 Labo; mediXtech Japan, 1.1 Gy/min). All the cases other than visualizing CtIP, RPA2, and gH2AX,
cells were fixed with 20Cmethanol for 5 min and then re-fixed with 3% formaldehyde in 250mM HEPES pH 7.4 at R.T. for 10 min.
For visualization of CtIP or RPA2, cells were fixed with 3% formaldehyde in 250mM HEPES pH 7.4 containing 0.5% Triton X-100 one4 Cell Reports 36, 109383, July 13, 2021
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OPEN ACCESSice for 0.5 h. For gH2AX, fixation was essentially performed as that for CtIP and RPA2 without 0.5% Triton X-100. Fixed cells were
permeabilized with 0.5% Triton X-100 on ice for 5 min, and blocked with 0.1% BSA in PBS on ice for 20 min. After that cells were
incubated with primary antibodies at R.T. for 1 hour, followed by incubation with fluorochrome-conjugated secondary antibodies
along with Hoechst for 30 min. Coverslips were finally mounted ProLong Gold (Thermo Fisher). If assignment of S/G2 or G2 cells
was indicated, cells were co-stained with cyclin A, or treated with 10 mM EdU for 10min before fixation, respectively. EdU click-iT
chemistry was performed as manufacturer’s instructions (Thermo Fisher). Cell images were essentially captured using a confocal
laser microscope (C2 system connected to a Ti-E inverted microscope; Nikon). For BRCA1 IRIF and NBS1 visualizations, cell images
were captured using a Andor Zyla 5.5 cCMOS camera connected to amicroscope (Ti-E invertedmicroscope; Nikon). To count all foci
in a nucleus, five z axis with 0.4-mm interval imageswere stacked. The number of the nuclear focus signals was automatically counted
using Nis-Elements software version 5.20 (Nikon) (Isobe et al., 2017).
Proximity ligation assay (PLA)
Proximity ligation assaywas performed basically as for the immunofluorescence procedure up to the primary antibody treatment (see
details above) and then treated with PLA-probe-conjugated secondary antibodies, followed by ligation and amplification steps ac-
cording to the manufacturer’s protocol (Duolink in situ proximity ligation assay, Sigma-Aldrich). Signals were captured by confocal
laser microscope and the number of the nuclear focus signals counted (see above in Method details).
Western blotting and immunoprecipitation
Protein extraction, immunoprecipitation and western blotting were performed as described (Nozawa et al., 2010). For whole cell pro-
tein extraction, cells were lysed in SDS buffer (62.5 mM Tris-HCl pH6.8, 1% SDS, 10% glycerol, 0.625% 2-Mercaptoethanol). The
extracts from 1.0 3 105 cells were separated by precast gels (FUJIFILM Wako) for Figures 1B, S1B, S3, S4A, and S5A or house-
made gels for Figure 3B and S2B. Transfer of proteins onto PVDF membranes and incubation with primary/secondary antibodies
were performed by standard procedures. The blots probed with secondary antibodies conjugated with horse radish peroxidase
were exposed with ImmunoStar (FUJIFILMWako) and imaged with LumiVision PRO 400EX system (AISIN) or LuminoGraph I system
(ATTO). Quantifications of bands intensity were done by ImageJ (Figure S4A).
For immunoprecipitation, cells were lysis with CSK buffer (0.5 M NaCl, 0.1% Triton X-100, 10 mM PIPES-NaOH pH 7.0, 300 mM
sucrose, 1 mM MgCl2, 1 mM EDTA) supplemented with 100 mM PMSF (phenylmethanesulfonylfluoride) and 2 mg/ml leupeptin, and
centrifugated supernatant was used as nuclear extract. Anti-FLAGM2 Affinity Gel (Sigma-Aldrich) was used for immunoprecipitation
of FLAG-tagged RIF1 complexes from the nuclear extracts.
Mass spectrometry analysis
Proteomic analysis using mass spectrometry was performed as described (Nozawa et al., 2010). Briefly, samples were separated by
12.5% gel of SDS–PAGE, and each lane was cut into nine pieces for trypsinization for liquid chromatography coupled to tandemMS
(LC/MS/MS). The raw data files were searched against the international protein index human database (version 3.63) including with
Mascot software (Matrix Science). The number of unique spectra and the percent coverage were computed from data summarizing
two measurements from all pieces of a gel and identified for each protein was converted to emPAI (exponentially modified protein
abundance index) values. Specific peptides for PP1a, PP1b and PP1g were detected, respectively. Common peptides among the
subtypes were assigned to the all subtypes, respectively. When no spectrum was identified, the number of unique spectra was
considered as 0.8 to avoid underestimation because of the detection limit.
Quantitative real-time PCR
To evaluate the efficiency of SHLD2 knockdown, we used quantitative PCR analysis. Total RNA from siRNA-treated HeLa cells was
extracted using ISOGEN (FUJIFILM Wako), according to the manufacturer’s protocol. The total RNA was reverse transcribed using
the TaKaRa RNA PCR Kit (AMV) ver.3.0. Quantitative real-time PCR was performed according to standard procedures using
TB Green Premix Ex TaqII (TaKaRa) and Mx3000P (STRATAGENE). Primer sets: SHLD2 (50– ccacgcagtactaagagttg–30 and 50– ggc
ctgttccactgttaac–30), GAPDH (50– ctctccagaacatcatccc–30 and 50– ctagacggcaggtcaggtc–30)
Colony formation assay
For colony formation assay, following steps were performed. Doxycycline was added 24 hours after transfection with siRNA (control
or BRCA1), and then after 24 hours, 500-1000 cells were plated in each well of a 6-well plate. Olaparib (Selleckchem) was added at
the indicated doses 8 h after the plating. After 72 hr incubation, Olaparib and Doxycycline were washed out and replaced with fresh
medium. One week later, the colonies were fixed with methanol at20C for 5 min and stained with Giemsa solution. Colonies were
counted and the surviving rates were calculated as ratios to the number of those without Olaparib.
DSB reporter assay
ADSB reporter assays usingU2OSEJ5-GFP (for NHEJ) orU2OSDR-GFP (for HR)were performedessentially as described (Gunn and
Stark, 2012; Isobe et al., 2017). 24 h after siRNA transfection byRNAiMAX (Life Technologies), cells were transfer to newwell with dilu-
tion. After subsequent 24 h, cells were transfectedwith siRNA, plasmid for I-SceI expression, and plasmids formCherry expression orCell Reports 36, 109383, July 13, 2021 e5
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OPEN ACCESSmCherry-tagged siRNA-resistant RIF1 derivatives by Lipofectamine 2000 (Life Technologies). Then, after 72 h incubation, GFP- and
mCherry-positive cells were counted by flow cytometry (Cell Sorter SH800S; Sony).
QUANTIFICATION AND STATISTICAL ANALYSIS
For bee swarm plot, statistical significance was determined by Mann-Whitney U-test using R software ‘‘*,’’ ‘‘**,’’ and ‘‘***’’ means p
value < 0.001. The number of experimental replicates is stated as ‘‘n’’ in the figure legend. Error bars represent standard deviation
between the experiments analyzed with R software, as indicated in the legends.e6 Cell Reports 36, 109383, July 13, 2021
